Solventum Corporation
69.78-1.14 (-1.61%)
Oct 29, 4:00:02 PM EDT · NYSE · SOLV · USD
Key Stats
Market Cap
12.10BP/E (TTM)
32.01Basic EPS (TTM)
2.18Dividend Yield
0%Recent Filings
8-K
New CCO appointment announced
Solventum Corporation appointed Heather Knight as Chief Commercial Officer effective November 10, 2025, to oversee global commercial and R&D operations across its MedSurg, Dental Solutions, and Health Information Systems segments, reporting to CEO Bryan Hanson. This move coincides with Chris Barry's departure as Executive Vice President and Group President of MedSurg on December 31, 2025, after which he receives severance under the company's plan. Knight's 30 years in MedTech, including her recent COO role at Baxter, positions her to drive integrated growth. Leadership shifts like this sharpen focus amid segment demands.
8-K
Upsized $2B note tender results
Solventum upsized its note tender offers to $2 billion on September 8, 2025, after strong early participation exceeded caps. The company will accept $650 million of 5.450% notes due 2027 at $1,021.65 per $1,000, $797 million of 5.400% notes due 2029 at $1,048.41, $458 million of 6.000% notes due 2064 at $1,042.69, and $22 million of 5.900% notes due 2054 at $1,046.10, with prorated allocations. Funded by its recent purification business sale to Thermo Fisher, this refines Solventum's debt profile. Settlement hits September 10.
8-K
Solventum sells P&F business
Solventum completed the sale of its Purification & Filtration business to Thermo Fisher Scientific on September 1, 2025, for $4.0 billion in cash before adjustments, excluding the drinking water filtration unit. This divestiture accelerates Solventum's transformation plan, with net proceeds of $3.4 billion earmarked mainly for debt reduction, bolstering the balance sheet. Updated 2025 guidance lifts adjusted EPS to $5.88-$6.03 while trimming net interest expense to $400 million. Yet risks from economic shifts loom large.
8-K
Solventum starts $1.75B note tenders
Solventum Corporation launched cash tender offers on August 22, 2025, to repurchase up to $1.75 billion of its senior notes across two pools, targeting shorter-term debt like the 5.450% notes due 2027 (capped at $500 million principal) and longer-term ones due 2054 and 2064. The offers, expiring September 22 with early tenders by September 5, hinge on proceeds from the pending sale of its purification and filtration business to Thermo Fisher Scientific. This move streamlines Solventum's debt profile amid market flux. Completion remains uncertain.
8-K
3M sells Solventum shares
Solventum Corporation announced a secondary offering where 3M Company sold 8,800,000 shares of Solventum common stock to underwriters Goldman Sachs and BofA Securities, priced to yield 3M gross proceeds of approximately $648 million. The sale closed on August 15, 2025, under a shelf registration, with Solventum issuing no shares and receiving no proceeds. This reduces 3M's stake post-spin-off. No impact on Solventum's operations.
IPO
Website
Employees
Sector
Industry
AVTR
Avantor, Inc.
11.58-3.50
BSX
Boston Scientific Corporation
100.30-0.67
HOLX
Hologic, Inc.
73.98-0.03
INFU
InfuSystems Holdings, Inc.
10.52+0.07
ISRG
Intuitive Surgical, Inc.
537.59-7.80
NVST
Envista Holdings Corporation
19.98-0.08
OMI
Owens & Minor, Inc.
5.22-0.06
RMD
ResMed Inc.
253.62-2.95
XRAY
DENTSPLY SIRONA Inc.
12.86-0.21
ZIMV
ZimVie Inc.
18.99+0.00